BRIEF-Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020

Reuters2023-02-06

Feb 6 (Reuters) - Merck & Co Inc :

* NABRIVA THERAPEUTICS - ON JAN 31, CO'S UNIT ENTERED INTO LETTER AGREEMENT WITH 2 UNITS OF MERCK & CO, ABOUT DISTRIBUTION AGREEMENT, DATED JULY 15, 2020

* NABRIVA THERAPEUTICS - PURSUANT TO LETTER AGREEMENT, CO'S EXCLUSIVE LICENSE TO DISTRIBUTE, COMMERCIALIZE SIVEXTRO WAS CONVERTED TO NON-EXCLUSIVE LICENSE

* NABRIVA THERAPEUTICS - PURSUANT TO LETTER AGREEMENT, CO'S UNIT AND MERCK'S 2 UNITS AGREED TO TERMINATE DISTRIBUTION AGREEMENT, EFFECTIVE JUNE 30

* NABRIVA THERAPEUTICS - COMPANY NO LONGER INTENDS TO ACTIVELY PROMOTE SIVEXTRO

* NABRIVA THERAPEUTICS - EXPECTS TO CONTINUE TO MAKE SIVEXTRO AVAILABLE TO WHOLESALE CUSTOMERS & RECORD REVENUE ON ACCOUNT OF ANY SALES UNTIL JUNE 30

Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2309362851?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-02-06 19:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2309362851","market":"us","top_or_hot":-1,"title":"BRIEF-Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020","media":"Reuters","content":"<html><body><p>Feb 6 (Reuters) - Merck &amp; Co Inc   :</p><p>   * NABRIVA THERAPEUTICS - ON JAN 31, CO'S UNIT ENTERED INTO LETTER AGREEMENT WITH 2 UNITS OF MERCK &amp; CO, ABOUT DISTRIBUTION AGREEMENT, DATED JULY 15, 2020</p><p>   * NABRIVA THERAPEUTICS - PURSUANT TO LETTER AGREEMENT, CO'S EXCLUSIVE LICENSE TO DISTRIBUTE, COMMERCIALIZE SIVEXTRO WAS CONVERTED TO NON-EXCLUSIVE LICENSE</p><p>   * NABRIVA THERAPEUTICS - PURSUANT TO LETTER AGREEMENT, CO'S UNIT AND MERCK'S 2 UNITS AGREED TO TERMINATE DISTRIBUTION AGREEMENT, EFFECTIVE JUNE 30</p><p>   * NABRIVA THERAPEUTICS - COMPANY NO LONGER INTENDS TO ACTIVELY PROMOTE SIVEXTRO</p><p>   * NABRIVA THERAPEUTICS - EXPECTS TO CONTINUE TO MAKE SIVEXTRO AVAILABLE TO WHOLESALE CUSTOMERS &amp; RECORD REVENUE ON ACCOUNT OF ANY SALES UNTIL JUNE 30</p><p>Further company coverage:   </p><p>((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-06 19:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Feb 6 (Reuters) - Merck & Co Inc   :   * NABRIVA THERAPEUTICS - ON JAN 31, CO'S UNIT ENTERED INTO LETTER AGREEMENT WITH 2 UNITS OF MERCK & CO, ABOUT DISTRIBUTION AGREEMENT, DATED JULY 15, 2020   * ...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999015341.SGD","symbol_name":"United Income Focus Trust Acc SGD-H","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2309362851","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2309362851","pubTimestamp":1675682097,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Feb 6 (Reuters) - Merck & Co Inc   :   * NABRIVA THERAPEUTICS - ON JAN 31, CO'S UNIT ENTERED INTO LE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","MRK":"默沙东","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0122379950.USD":"贝莱德世界健康科学A2","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","BK4516":"特朗普概念","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999014559.SGD":"United Income Focus Trust Dis SGD","BK4007":"制药","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4559":"巴菲特持仓","LU0861579265.USD":"联博低波幅策略股票基金A","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4550":"红杉资本持仓","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H"},"translate_title":"简介——Nabriva Therapeutics——1月31日，Co的部门与Merck&Co的两个部门就2020年7月15日的分销协议签订了书面协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UNT":1,"MRK":1,"NBRV":0.9},"content_text":"Feb 6 (Reuters) - Merck & Co Inc   :   * NABRIVA THERAPEUTICS - ON JAN 31, CO'S UNIT ENTERED INTO LETTER AGREEMENT WITH 2 UNITS OF MERCK & CO, ABOUT DISTRIBUTION AGREEMENT, DATED JULY 15, 2020   * NABRIVA THERAPEUTICS - PURSUANT TO LETTER AGREEMENT, CO'S EXCLUSIVE LICENSE TO DISTRIBUTE, COMMERCIALIZE SIVEXTRO WAS CONVERTED TO NON-EXCLUSIVE LICENSE   * NABRIVA THERAPEUTICS - PURSUANT TO LETTER AGREEMENT, CO'S UNIT AND MERCK'S 2 UNITS AGREED TO TERMINATE DISTRIBUTION AGREEMENT, EFFECTIVE JUNE 30   * NABRIVA THERAPEUTICS - COMPANY NO LONGER INTENDS TO ACTIVELY PROMOTE SIVEXTRO   * NABRIVA THERAPEUTICS - EXPECTS TO CONTINUE TO MAKE SIVEXTRO AVAILABLE TO WHOLESALE CUSTOMERS & RECORD REVENUE ON ACCOUNT OF ANY SALES UNTIL JUNE 30Further company coverage:   ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2309362851"}